BiotechTube

Quadravalent human papillomavirus vaccine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Late Complication From Kidney Transplant

Conditions

Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma

Trial Timeline

Oct 1, 2013 → Dec 1, 2017

NCT ID
NCT02624349

About Quadravalent human papillomavirus vaccine

Quadravalent human papillomavirus vaccine is a approved stage product being developed by Merck for Late Complication From Kidney Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT02624349. Target conditions include Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02624349ApprovedCompleted

Competing Products

20 competing products in Late Complication From Kidney Transplant

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
77
AL001 + PlaceboAlectorPhase 2
44
89Zr-DFO-AP-101Eli LillyPhase 1
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
Sarpogrelate Sustained Release/Aspirin + AspirinYuhanApproved
85
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
77
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPre-clinical
23
volociximabAstellas PharmaPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 1
33
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
77
E10030Astellas PharmaPhase 1
33
Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATGAstellas PharmaApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85